1. By-Covid
  2. All content
  3. Cessda
Please use this identifier to cite or link to this item: https://t2-4.bsc.es/jspui/handle/123456789/59699
Full metadata record
DC FieldValueLanguage
dc.creatorH.Al Wattar, B, University of Warwicken
dc.creatorFisher, M, University Hospital Coventry & Warwickshireen
dc.creatorBevington, L, University Hospital Coventry & Warwickshireen
dc.creatorTalaulikar, V, University College London Hospitalsen
dc.creatorDavies, M, University College London Hospitalsen
dc.creatorConway, G, University College London Hospitalsen
dc.creatorYasmin, E, University College London Hospitalsen
dc.date2021-04-14T00:00:00Zen
dc.identifier854760-
dc.identifier10.5255/UKDA-SN-854760-
dc.identifierhttps://doi.org/10.5255/UKDA-SN-854760-
dc.identifier.urihttps://t2-4.bsc.es/jspui/handle/123456789/59699*
dc.descriptionClinical practice guidelines (CPGs) are key instruments to implement the practice of evidence-based medicine. We aimed to evaluate the methodological quality and variations in CPGs recommendations on the diagnosis and management of polycystic ovary syndrome (PCOS). We searched MEDLINE, EMBASE, and CENTRAL until December 2020 for all evidence-based CPGs and consensus statements on PCOS. We extracted data in duplicate to map clinical recommendations across pre-specified disease domains and assessed CPGs methodological quality of using the AGREE II tool. We included thirteen PCOS CPGs were published between 2007-2018. CPGs recommendations were mostly focused on screening for and managing metabolic disease (12/13, 92%), followed by cardiovascular risk assessment (10/13, 77%). Mental health (8/13, 62%) and diagnosis in adolescents (7/13, 54%) were the least reported domains. Most CPGs had a high quality for scope and purpose description (12/13, 92%) while stakeholder’s involvement and applicability of recommendations to clinical practice were appropriate in only two CPGs (2/13, 15%). We identified inconsistency in recommendations on PCOS diagnosis in adolescents, optimal lifestyle interventions, hirsutism and acne treatments, interventions to reduce the risk of ovarian hyperstimulation syndrome, the frequency and screening criteria for metabolic and cardiovascular disease, and on optimal screening tools for mental health illness in women with PCOS. Current CPGs on the diagnosis and management of PCOS vary in their scope and methodological quality which may hinder evidence translation into clinical practice. We identified disease domains with existing evidence gap to guide future research and guideline updates.en
dc.languageen-
dc.rightsBassel H.Al Wattar,en
dc.subjectQUALITYen
dc.subjectPOLYCYSTIC OVARY SYNDROMEen
dc.subjectCLINICAL GUIDELINEen
dc.subjectSYSTEMATIC REVIEWen
dc.subjectEVIDENCE SYNTHESISen
dc.subject2021en
dc.titleClinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study, 2007-2018en
dc.typeDataseten
dc.coverageUnited Kingdomen
Appears in Collections:Cessda

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.